Interventions for Human Frailty: Physical Activity as a Model

Linda P. Fried
Columbia University Medical Center, New York, New York 10032
Correspondence: lpfried@columbia.edu

In the last 100 years, populations in developed countries have experienced an unprecedented addition of 30 years to life expectancy. Developing countries are now experiencing this same phenomenon, but over a shorter time frame. With this success comes the challenge of maximizing health and vitality across these added years. The compression of morbidity to the latest point in the human life span could unleash a sustained third demographic dividend that benefits all of society. To accomplish this, society needs to invest in the prevention and treatment of frailty, as well as in the prevention of chronic diseases at every age and stage of life. A model intervention, physical activity, may offer a road map.

COMPLETING THE TRANSITION TO A WORLD OF LONGER LIVES: OPTIMIZING HEALTH ACROSS OUR LONGER LIFE COURSE

In the last 100 years, developed countries have experienced the unprecedented addition of 30—and more—years to life expectancy. Many developing countries are now experiencing this same extension in life expectancy, but generally over a much more compressed time frame of approximately 40 years. In all of these societies, this unprecedented addition of years of life has been because of public health interventions that have targeted infectious diseases and decreased early childhood and maternal mortality. Having now added, essentially, a new stage of life, the critical challenge is to understand how to maximize health and vitality across these longer years. Accomplishing this is essential to unleashing the opportunities and benefits of our longer lives—for older adults themselves and for all ages (Fried 2015). This goal has been expressed as the need to “compress morbidity” to the latest point in the human life span so that people live free of the diseases and conditions of old age for much of that old age (Fries 2001). If accomplished, a compression of morbidity could unleash a sustained third demographic dividend for all of society. However, to accomplish this requires society investing in creating what we could term a new life stage in which a healthy older population is able to make significant contributions to societal well-being and productivity (Fried in press a).

Accomplishing this compression of morbidity requires two significant components. First is investing in the prevention of the development of chronic diseases at every age and stage of life, which is described as a life course approach to prevention (Fried in press a). There is evidence that people who arrive at age 70 in good health...
are at high likelihood of remaining healthy into their later years (Fried in press a). On the other hand, those with cumulative exposures to adverse risk factors across childhood and adulthood manifest single and then multiple diseases as they get older, and are likely to become disabled secondary to these diseases as early as their 50s and 60s (Wolinsky et al. 1983; Levine and Crimmins 2014; Geronimus et al. 2015; Fried and Ferrucci, in press).

The second approach focuses on optimizing health and preventing or slowing the onset of frailty, dementia, multimorbidity, and disability in older age itself. The remainder of this article considers the issue of frailty and the opportunities for delaying, preventing, or treating frailty, considering insights offered from a model intervention: physical activity.

AGING AND DISEASE

Population-based research is now offering evidence, across multiple studies, that the process of aging can be distinguished from the processes and consequences of diseases. The first stage of such research, over the last 50 years, showed that diseases of specific organ systems, such as atherosclerotic disease of the heart, brain, and peripheral vasculature, could be understood mechanistically as processes distinct from aging itself. These observations led to substantial research that showed that many chronic diseases are, in fact, preventable into the oldest ages. The implications, of course, are that these diseases were not inevitable with aging or, at least, not tied to a chronological age. Other innovative observations have suggested that a focus on investigating individual end-organ diseases misses a major conclusion of mechanistic research: that there are shared risk factors and etiologic pathways for multiple chronic diseases. At the behavioral level, these risk factors include physical activity, smoking, and diet, and, at the intrinsic level, there are mechanisms in common for multiple chronic diseases, such as inflammation (Tinetti and Fried 2004; Fried and Ferrucci, in press).

Parallel research has been increasingly seeking to characterize, in humans, the independent contributions of aging itself to health outcomes independent of superimposed chronic diseases. Interestingly, in multivariate analyses in a population-based cohort study, the Cardiovascular Health Study, specific chronic diseases are the independent predictors of 5-year mortality into the oldest ages; however, after 85 years, age becomes an additional independent predictor (Fig. 1). This suggests the influence of biologic

Figure 1. Age emerges as an independent predictor of mortality, independent of chronic diseases, beginning at age 85 years, based on analyses in community-dwelling men and women 65 years and older in four U.S. communities participating in the Cardiovascular Health Study. (From Fried et al. 1998; reprinted, with permission.)
aging as a force for mortality, emerging independently of disease in the oldest old. Additionally, new research suggests that biologic aging can be characterized using population-based approaches as the composite of altered physiologic regulation and function across multiple systems. With this approach, longitudinally, young as well as older adults show differentiation between biologic and chronologic age, potentially as young as the mid-30s (Cohen et al. 2014; Belsky et al. 2015; Cohen et al. 2015).

THE EMERGENCE OF FRAILTY IN OLDER AGE

With increasing age, after about age 70, a new phenotype emerges, which is distinct from any single chronic disease and is an independent predictor of mortality in the short (3 yr) and intermediate (7 yr) term: that of frailty. This phenotype (Table 1) meets the criteria for a medical syndrome (Fried et al. 2001; Bandeen-Roche et al. 2006; Morley et al. 2013). Criteria consist of a critical mass of three to five clinical components, including muscle weakness, slowed gait, low physical activity, sense of low energy or exhaustion, and unintentional weight loss. For 90% of those who become frail, frailty is chronic and progressive in its development (Xue 2011). Those with a subclinical presentation of only one or two components are at 2.5-fold increased risk of progressing to having three to five components present in 3 yr with full manifestation of the frailty phenotype (Fried et al. 2001). The prevalence of frailty increases with age after age 65, and is twice as prevalent in women as men and African-Americans as whites (Fried et al. 2001; Hirsch et al. 2006). By age 85, ~25% of older adults in the community manifest this phenotype; that is, they show three, four, or five components of frailty (Fried et al. 2001).

The characteristics of the phenotype were originally hypothesized to be a vicious cycle resulting from dysregulated energetics (Fig. 2). Such a cycle can be potentially initiated at any point, but the evidence is that in most older adults who become frail, it begins with declines in strength, walking speed, and/or physical activity and then progresses to also include self-reported low energy or exhaustion, and significant unintended weight loss (Xue 2011).

Notably, this phenotypic presentation has the characteristics of a medical syndrome: a constellation of symptoms and signs, when present in a critical mass, which predicts both characteristic outcomes and identifies a distinct underlying pathophysiology. The critical mass of criteria that are present have greater specificity for both outcomes and pathophysiology than any one or two factors (Fried et al. 2001; Bandeen-Roche et al. 2006). This constellation of factors has been shown to have the dynamics of a clinical syndrome in which there are no distinct subsets of criteria that cluster together, and any three (of five) factors that are present synergistically predict outcomes of mortality, disability onset and progression, hospitalization, falls, and nursing home admission, significantly more than any one or two factors (Bandeen-Roche et al. 2006). It has recently been recommended, in an international consensus conference, that frailty be considered a

Table 1. Criteria that define frailty

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Criteria for frailty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight loss</td>
<td>Lost &gt;10 pounds unintentionally last year</td>
</tr>
<tr>
<td>Exhaustion</td>
<td>Felt last week that “everything I did was an effort” or “I could not get going”</td>
</tr>
<tr>
<td>Slowness</td>
<td>Time to walk 15 feet (cutoff depends on sex and height)</td>
</tr>
<tr>
<td>Low activity level</td>
<td>Expends &lt;270 kcal/week (calculated from activity scale incorporating episodes of walking, household chores, yard work, etc.)</td>
</tr>
<tr>
<td>Weakness</td>
<td>Grip strength measured using hand dynamometer (cutoff depends on sex and body mass index [BMI])</td>
</tr>
</tbody>
</table>

From Fried in press b; reprinted, with permission.

*Syndrome present when more than three characteristics are identified.

*For specific measures and details for determining frailty criteria, see Fried et al. 2001.
new medical syndrome (Morley et al. 2013) and that clinicians screen for frailty in people 70 and older as a basis for intervening to prevent or alleviate further decline.

MECHANISMS UNDERLYING THE CLINICAL SYNDROME OF FRAILTY

Consistent with the definition of a syndrome, the clinical presentation, or phenotype, identifies a specific etiologic pathophysiology. The extant evidence is briefly summarized here, considering both physiologic and biologic genesis.

First, there are a number of individual physiologic systems that have been identified as dysregulated in association with frailty. As background, there are many data that indicate declines with age in function of multiple functional and regulatory systems in the body, such as circulating levels of specific hormones (e.g., estrogens, testosterone, and insulin-like growth factor 1 [IGF-1]) (Kuchel et al. 2001), impaired insulin sensitivity (Davidson 1979; DeFronzo 1981; Shimokata et al. 1991; Scheen 2005; Metter et al. 2008), along with elevations of markers of inflammation (e.g., interleukin 6 [IL-6] and C-reactive protein [CRP]) with aging (Ershler and Keller 2000; Reuben et al. 2002; Cohen et al. 2003; Joseph et al. 2005). Dynamic interactions between declines in gonadal hormones and increases in inflammatory mediators affect bone mass, as well as mobility (Cappola et al. 2003), whereas the impaired insulin sensitivity is predictive of both frailty and diabetes (Kalyani et al. 2012b). Notably, observations on insulin resistance indicate that, although this becomes ap-
parent in the vast majority of women > 85, frailty is associated with highest levels of dysregulation. For example, as exemplified for insulin resistance–homeostatic model assessment (IR-HOMA) (Barzilay et al. 2007) or glycated hemoglobin (HgbA1C) (Kalyani et al. 2012b), an HgbA1C of 6.5% and 8.0% or greater, respectively, are associated with frailty prevalence (Blaum et al. 2009) and threefold higher incidence (Kalyani et al. 2012b). In the latter study, the association of HgbA1C with frailty incidence is nonlinear. This suggests that the change in physiologic function with aging is associated with frailty past a threshold level of severity.

With this pattern in mind, I briefly summarize here the physiologic and biologic systems shown, to date, to be associated—when dysregulated—with the syndrome of frailty. For example, frail men and women 65 and older have lower muscle density and muscle mass and higher fat mass than do nonfrail persons (Cesari et al. 2006). Phenotypic frailty is also associated with altered resting metabolic rate (Weiss et al. 2012). Elevation of the following physiologic systems have been associated with the phenotype of frailty: elevated glucose and insulin in response to glucose tolerance test and elevated HgbA1C (Kalyani et al. 2012b), IR-HOMA, and inflammation (Walston et al. 2002; Barzilay et al. 2007); higher evening cortisol levels (Varadhan et al. 2008; Johar et al. 2014); elevated white blood cell counts (Baylis et al. 2013); and increased heart rate variability in association with frailty (Chaves et al. 2005). Along with the direct association between level of inflammation and frailty, there is an increase in frailty with the number of inflammatory diseases present (Chang et al. 2012).

Systems that are lower in association with frailty are: IGF-1, testosterone, dehydroepiandrosterone sulfate (DHEA-S), markers of clotting (Walston et al. 2002; Kalyani et al. 2012a), hemoglobin (Chaves et al. 2005), and serum carotenoid and micronutrient concentrations, with greater likelihood of multiple micronutrient deficiencies (Michelon et al. 2006). Low daily energy intake (<21 kcal/kg) is associated with 24% increased risk of frailty (Bartali et al. 2006). Low protein and vitamins D, C, and folate intakes are also associated with frailty, along with low intake of more than three nutrients.

Further, there is mounting evidence that biologic systems that are altered with aging also predict frailty. For example, building on the hypothesis that dysregulated energetics may underlie the development of frailty (Fried 2001), increasing attention is being focused on mitochondrial dysfunction. There is now strong evidence for such dysfunction with aging itself. The decline in mitochondrial function with aging limits production of adenosine triphosphate (ATP) (Chistiakov et al. 2014), which most prominently affects the function of tissues with high energy demand, for example, the nervous system, heart, and skeletal muscle. This has been shown to predict sarcopenia and loss of physical fitness and an increase in central obesity, diabetes, fatigue, and inflammation (Coen et al. 2013), all of which contribute to frailty. Now there is more specific implication of a mitochondrial genetic variant in frailty (Moore et al. 2010), and evidence that mitochondrial DNA (mtDNA) levels and number might form part of the biological component of the phenotype (Ashar et al. 2015). In separate studies, mtDNA copy number has been associated with ATP production rate (Short et al. 2005), and worsening in frailty status is associated with a significant decrease in global DNA methylation levels (Bellizzi et al. 2012). These findings support the theory that aging-associated decrease in mitochondrial function, with alterations in production of energy, might underlie both the phenotype and dysregulations of frailty.

Second, the whole is greater than the sum of the parts. It is clear that these individual systems are not independent of each other. For example, sarcopenia results, in part, both from hormonal deficiency and cytokine excess (Newman et al. 2001; Morley et al. 2005). Postmenopausal declines in serum estrogen and androgen levels contribute to increased bone loss (Joseph et al. 2005). Higher serum testosterone in older women is associated with insulin resistance (IR) and metabolic syndrome (Patel et al. 2009). Both IR and diabetes have been associated with excessive loss of lean body mass and
muscle strength (Park et al. 2007, 2009). Further, IR is associated with skeletal muscle mitochondrial dysfunction (Phielix et al. 2008). Many physiological declines are mediated by proinflammatory cytokines, decline in hormones (especially, testosterone [T] and IGF-1), and IR; this has been well summarized by Morley et al. (2005). Further, inflammation is associated with lower leg muscle mass and strength, IR, frailty, and disability (Guralnik et al. 1994; Ferrucci et al. 2002; Visser et al. 2002; Hubbard et al. 2010).

With regard to frailty, prevalence and incidence of frailty is a product of the multiplicity of dysregulated systems, more than any one system. Overall, it has been shown that there is a nonlinear association of the number of systems dysregulated with frailty (Fried et al. 2009), and even within systems, the number of abnormal hormones (Cappola et al. 2003) or micronutrients (Semba et al. 2006) associated with frailty. Further, higher cortisol, DHEA-S ratio, as well as lower levels of DHEA-S and higher white blood cell counts predicted frailty over 10-yr follow-up, indicating interactions between the immune and endocrine axis (Baylis et al. 2013). One summary has stated that the “presence of decreased gonadal hormones and IGF-1, combined with unusually high peripheral levels of cytokines, inflammatory mediators, and coagulation markers all enhance risk of sarcopenia and frailty” (Joseph et al. 2005).

The nonlinear association of the number of systems dysregulated with the probability of frailty is consistent with frailty emerging from severe dysregulation of the complex dynamical system that maintains organismal homeostasis and resilience (Fried et al. 2009). As shown in Figure 3, there is a nonlinear increase in the prevalence of the phenotype of frailty as the number of abnormal physiologic systems increases in women 70–79 in the Women’s Health and Aging Studies. The systems considered here include: hematological (hemoglobin >12 mg/dL); inflammatory (IL-6 top tertile); hormonal (deficiencies in IGF-1, DHEA-S, and HgbA1C); adiposity (lowest quartile, triceps skinfold thickness); neuromuscular (slow fine motor speed); and two or more micronutrients deficient. Further, the population subdivided into two classes: 70% with one or no systems abnormal, and 30% with multiple systems (2.9, on average) abnormal; thus, three or more systems abnormal predict being frail. Notably, there were no dominating patterns of systems involved in association with frailty. However, the second class showed an odds ratio of 2.6 ($p < 0.05$) in association with being frail, adjusting for comorbid diseases, age, race, and education (Fried et al. 2009). Class 2 was associated with being frail after individually controlling for each of the eight systems, and none of the eight systems were individually significant except fine motor speed. Notably, the number

Figure 3. Association of number of physiological systems at abnormal levels with prevalence of being frail, women aged 70–79 ($p < 0.01$ for quantitative trend). (From Fried et al. 2009; reprinted, with permission.)
of comorbid diseases was also associated with frailty, but independent of multisystem abnormalities; the strength of association approximated that of class 2. These findings support the biology underlying the phenotype of frailty as being that of a complex system, with the dominating predictor being the number of systems dysregulated, not any particular system.

The picture gets even more complex when one considers that the physiological systems implicated in frailty each affect two or more of the five components of the frailty phenotype and further mutually affect or regulate each other. The substantial network of physiologic connections implied here is consistent with the interconnected systems of feedforward and -back loops that are elements of a complex dynamical system. It has been suggested that the aggregate effect of senescent processes, such as those in the systems studied here, have a nonlinear contribution to a complex system (Yates 2002), even if their decline over the adult life course displays a quasilinear property individually. The findings summarized above are consistent with this theory, and with the concept of a complex adaptive system in which dysregulation of a threshold number of systems may culminate in critical loss of homeostatic adaptive capacity. This emergent property of frailty as the manifestation of a dysregulated complex adaptive system is essential for resiliency (Fried et al. 2009).

Third, there is evidence that this dysregulated complex system is particularly manifest in the response to a challenge or stressor, and may well underlie the high risk of adverse outcomes in frailty. In a series of studies of response to an oral glucose tolerance test administered to 85- to 95-yr-old women in the Women’s Health and Aging Study II, >70% had compromised response to the glucose tolerance test; only 27% had a normal fasting glucose and normal oral glucose tolerance test (OGTT). However, those who were frail had a differentially worse response. Specifically, women who were frail had 67 mg/dL greater increase in glucose in response to OGTT, and markedly delayed return of glucose and insulin back to baseline, compared with those who were nonfrail or prefrail (Kalyani et al. 2012b).

Further, frail women showed abnormal hormonal stimulus-response dynamics in energy metabolism response after oral glucose load (Kalyani et al. 2012a), with a pattern of elevated glucose-raising hormones and decreased glucose-lowering hormones in the frail compared with the nonfrail. Overall, the findings suggested that frailty status may represent a threshold of dysregulation in energy metabolism hormones, particularly for ghrelin. These findings support the theory that the entire physiological network of hormones that mutually regulate glucose homeostasis are dysregulated in frailty. This further supports the line of reasoning that intrinsic homeostatic mechanisms to maintain energy balance may be blunted with aging (Wilson and Morley 2003).

Overall, these findings are consistent with frailty as a marker of a severe end stage of biologic aging, with underlying dysregulation of the complex dynamical systems that maintain a resilient organism, and in which dysregulation of the system will become evident in the pres-
ence of stressors, with consequences, such as adverse health outcomes, which occur when the system is challenged. This theory is consistent with the basic tenets of biological complex systems (Csete and Doyle 2002; Kitano 2002). This complex system could well be considered a hallmark of aging, adding to the nine laid out by López-Otín et al. (2013).

IMPLICATIONS OF FRAILTY AS A DYSREGULATED COMPLEX SYSTEM FOR THERAPEUTIC OR PREVENTIVE APPROACH

Ultimately, the evidence of frailty as a complex system suggests why interventions targeting only one of many dysregulated systems, such as hormonal supplementation, have not been found to prevent or ameliorate frail states.

For example, many trials of monotherapies, such as replacement of estrogen or testosterone (Snyder et al. 1999; Taaffe et al. 2005; Ronkainen et al 2009; Kenny et al. 2010), for mitigation of frailty have not been successful. There are many other dimensions that need to be understood beyond this; for example, why is it that estrogen-replacement therapy does not protect against skeletal muscle loss with aging in women, whereas testosterone does predict muscle mass (Kenny et al. 2003)? With these observations as background, for the rest of this article we focus on the evidence of frailty as a complex system problem as the basis for a differential approach to prevention or treatment.

A particular focus to intervention within this framework could be the role of energy dysregulation as a critical entry point to development of frailty. Certainly, across the evidence summarized above, there are key elements of energy dysregulation now identified as components or drivers of frailty, from the altered energy intake in diet, to the phenotype itself, including unintentional weight loss, physical exhaustion and sarcopenia, and muscle weakness (Fig. 2) (Fried et al. 2001), to altered glucose metabolism and muscle efficiency, to mitochondrial function. Considering the evidence, this would suggest that therapeutic opportunities need to focus on improving energy production and use, and shifting the entire complex system of function.

PHYSICAL ACTIVITY AS A MODEL FOR INTERVENTIONS THAT MIGHT PREVENT, DELAY, OR TREAT FRAILTY

Physical activity, as an intervention, offers an intriguing model for the type of intervention that could prevent or mitigate frailty. This article concludes by offering the reasoning for this statement.

First, if one considers the association of physical activity with frailty, declines in physical activity both predict, early on, the development of the rest of the phenotype (Xue et al. 2012) and likely exacerbate both frailty-related outcomes and the underlying dysregulation. Consider in terms of outcomes that, although frailty has been shown to predict mortality, falls, and disability more powerfully than physical activity alone, low levels of physical activity, into the oldest ages, independently predict these outcomes, including mortality (Kushi et al 1997; Fried et al. 1998; Andersen et al. 2000; Katzmarzyk et al. 2003; Hu et al. 2004). Physical activity is consistently a predictor of lower mortality, as well as of greater muscle strength, into the oldest ages. In observational studies of older adults, for example, Xue et al. (2012) has shown in a 12-yr follow-up of women 70–79 at baseline in the Women’s Health and Aging Study II, that those who rapidly declined in physical activity over 12 yr or who were always sedentary (adjusting for chronic diseases, disability, obesity, and other confounders) had hazard ratios for death of 2.34 and 3.34, compared with those who were always active. Further, the findings suggested that physical activity did not have to be vigorous to have benefit (Xue et al. 2012).

Second, physical activity is known to preserve or improve the function of many of the physiologic systems at abnormal levels in frail older adults: for example, sarcopenia and protein synthesis (Zampieri et al. 2015), muscle force and function, and fiber morphology. Gómez-Cabello et al. (2014) showed that, in people 65 and older, physical activity in women was associated with both upper and lower body strength, whereas in men it was associated with strength of knee and grip. Further, exercise maintains or improves glucose metabolism, in-
flammation, and anemia, as well as exercise tolerance underlying the feeling of “exhaustion” or low energy in the phenotype.

Third, declines in energy availability to the individual because of impairment in ATP production with aging may depend on mitochondrial dysfunction (Trounce et al. 1989; Shigenaga et al. 1994), which itself is partially corrected by physical activity. Exercise has been shown to maintain mitochondrial function in aging and prevent release of reactive oxygen species (ROS). Regular exercise over adulthood not only preserves muscle force, function, and morphology, but preserves ultrastructure of intracellular organelles involved in calcium handling and ATP production, and lowers expression of genes related to autophagy and ROS detoxification, important for clearance of damaged organelles and proteins. Conversely, inactive aging results in drastic reduction in number of calcium release units and volume and number of mitochondria in muscle, compared with young individuals (Zampieri et al. 2015), as well as structure and preservation of organelle positioning—all dimensions that could directly influence ATP production and, thus, be important for overall muscle performance (Zampieri et al. 2015).

Notably, it appears possible to maintain a tuned energetics system with maintenance of physical activity over the life course and into the oldest ages. As reported by Zampieri et al. (2015), skeletal muscle of well-trained seniors with a 30-year history of regular exercise is more like that of young adults than that of age-matched sedentary individuals, and signaling pathways controlling muscle mass and metabolism are differently modulated in senior sportsmen to preserve bioenergetics characteristics and morphology, and that regular physical activity can now be seen as “a good strategy to attenuate age-related general decay of muscle structure and function” (Zampieri et al. 2015). Supporting this, as one outcome measure, the Health ABC study found in older participants followed for 5 yr that sedentary individuals had significantly increased risk of decline in gait speed to $0.60 \pm 0.03$ m/sec and/or inability to rise from a chair without use of arms (Peterson et al. 2009) compared with those who actively exercised. This suggests that self-selected exercise activities may be independently associated with delaying onset and progression of frailty (Peterson et al. 2009). Zampieri’s conclusion was that “a specific, well-directed program of training could improve body balance, muscle structure, and contractile properties in elderly persons” (Zampieri et al. 2015). In fact, exercise trials of different intensities in older adults of different degrees of frailty have shown the benefit. Notably, one of the first studies in this arena was that by Fiatarone et al. (1990), which showed an almost two-fold improvement of nonagenarian muscle strength and balance by a weight-lifting protocol. More recently, the LIFE Study randomized controlled trial showed that, among adults 70–89 at risk for disability (defined as sedentary, SPPB 9 or lower; could walk 400 m in $<15$ min; no major cognitive impairment), a struc-
tured, moderate intensity physical activity program that included aerobic (150 min per week of walking, with a goal of 30 min daily at intensity of 13), plus resistance and flexibility and balance training activities (compared with health education program) led to a significant difference in frailty prevalence at 12 mo (10%) compared with successful aging group (19%), and the mean number of frailty criteria was especially reduced for younger subjects, Blacks, participants with frailty, and those with multimorbidity (Pahor et al. 2014; Cesari et al. 2015).

**IMPLICATIONS**

Thus, trials of physical activity suggest that this offers a low-risk and effective preventive and therapeutic intervention to prevent or mitigate frailty. These findings are important in themselves. However, they offer intriguing implications in terms of criteria for other therapies to be considered in the future. These implications draw directly from further evidence, that physical activity “tunes”—or improves the function—of many systems in the body that are implicated in frailty etiology, as discussed above. These include muscle structure and function, hormonal, inflammatory, immune, hematologic, and other coregulatory functions, as well as supporting improved brain functions. Evidence ranges from trials of aerobic exercise training (for 6–9 mo), which showed improved heart rate variability in older adults (Levy et al. 1998; Schuit et al. 1999; Stein et al. 1999; Lipsitz 2002), to the metformin trial, which showed that the lifestyle intervention (with at least 150 min of physical activity per week) was more effective in restoring normal postload glucose values than was metformin or placebo, with the advantage of the lifestyle intervention being greater in older individuals (Nathan 2002), to the work of Lindholm et al. (2014); indicating

![Figure 4](http://perspectivesinmedicine.cshlp.org/)

**Figure 4.** Physical activity positively affects function of multiple components of the syndrome of frailty at levels of (A) frailty phenotype, (B) physiologic dysregulation, and (C) cellular function. DHEA-S, didehydroepiandrosterone sulfate; GH, growth hormone; HPA, hypothalamic–pituitary–adrenal; SNS, sympathetic nervous system.
that exercise of one leg in human volunteers leads to leg-specific epigenetic benefits in muscle: in addition to increased mass, epigenetic benefits, including new methylation patterns in >5000 sites on genome of muscle cells, particularly affected many muscle enhancers in genome that amplify expression of proteins by genes. Most of the genes affected play a role in energy metabolism, insulin response, and inflammation in muscles.

Further, exercise offers an intriguing model of a single intervention with multisystem benefits (Fig. 4). This confers great efficiency, but it also offers a model for types of interventions that may be effective in frailty as the outcome of dysregulation of the well-tuned complex dynamical system of a resilient organism. This is because physical activity simultaneously upregulates many systems that mutually regulate each other in combination. Thus, the whole organism could be retuned to a higher functional level. This offers a model intervention that matches well a complex system problem. If monotherapies are not sufficient, then finding an intervention that “tunes” a critical mass of systems would be critical. Kitano (2007) has asserted that frailty is the consequence of a trade-off between robustness and fragility (Kitano 2007), with robustness contributing to homeostasis and maintenance of functionality. Bortz (2008) has further stated that “Frailty is an assertion of the loss of dynamics, body-wise and system-wide” and that “It is in the tuning of the entire orchestra of genes to the cueing ‘A’ of the oboe where health resides.” Physical activity offers both the first evidence as to effective approaches to preventing or treating frailty and a biologic model for future therapies.

REFERENCES


Chaves PHM, Semba RD, Leng SX, Woodman RC, Ferrucci L, Guralnik JM, Fried LP. 2005. Impact of anemia and


Interventions for Human Frailty: Physical Activity as a Model

Linda P. Fried

Cold Spring Harb Perspect Med published online May 3, 2016

Subject Collection Aging

Interventions for Human Frailty: Physical Activity as a Model
Linda P. Fried

How Research on Human Progeroid and Antigeroid Syndromes Can Contribute to the Longevity Dividend Initiative
Fuki M. Hisama, Junko Oshima and George M. Martin

Articulating the Case for the Longevity Dividend
S. Jay Olshansky

Metformin: A Hopeful Promise in Aging Research

Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life Span
Sofiya Milman and Nir Barzilai

Inhibition of the Mechanistic Target of Rapamycin (mTOR) —Rapamycin and Beyond
Dudley W. Lamming

The Emergence of Geroscience as an Interdisciplinary Approach to the Enhancement of Health Span and Life Span
Felipe Sierra

The Economic Promise of Delayed Aging
Dana Goldman

Translating the Science of Aging into Therapeutic Interventions
James L. Kirkland

The Companion Dog as a Model for the Longevity Dividend
Kate E. Creevy, Steven N. Austad, Jessica M. Hoffman, et al.

Has the Rate of Human Aging Already Been Modified?
S. Jay Olshansky

Past, Present, and Future of Healthy Life Expectancy
Hiram Beltrán-Sánchez, Samir Soneji and Eileen M. Crimmins

DNA Damage, DNA Repair, Aging, and Neurodegeneration
Scott Maynard, Evandro Fei Fang, Morten Scheibye-Knudsen, et al.

The Role of the Microenvironmental Niche in Declining Stem-Cell Functions Associated with Biological Aging
Nathan A. DeCarolis, Elizabeth D. Kirby, Tony Wyss-Coray, et al.

Biochemical Genetic Pathways that Modulate Aging in Multiple Species
Alessandro Bitto, Adrienne M. Wang, Christopher F. Bennett, et al.

The Aging Heart
Ying Ann Chiao and Peter S. Rabinovitch

For additional articles in this collection, see http://perspectivesinmedicine.cshlp.org/cgi/collection/

Copyright © 2016 Cold Spring Harbor Laboratory Press; all rights reserved